IN BRIEF: Ixico reaffirms growth guidance as half-year revenue rises

Ixico PLC - London-based medical research company, focused on analysing trial data using neuroscience imaging and biomarkers - Reports results for the six months ended March 31. Revenue increases 23% to GBP3.9 million from GBP3.2 million the year before, "driven by new contract wins, contract extensions and an increased volume of analyses". Pretax loss widens to GBP1.6 million from GBP889,000. Sales and marketing expenses increase 23% to GBP1.1 million from GBPGBP862,000, with total operating expenses increasing 19% to GBP3.3 million from GBP2.8 million. Order book totals GBP18.1 million at March 31, up from GBP13.1 million one year prior. Company reaffirms guidance of 15% revenue growth for the full year. Chief Executive Officer Bram Goorden says Ixico "is now in a more stable and resilient position" and "is well placed to deliver on its ambitions and create sustainable value in the years ahead."

Current stock price: 8.80 pence, up 30% on Tuesday afternoon in London

12-month change: down 2.3%

By Emma Curzon, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2026 Alliance News Ltd. All Rights Reserved.

Ixico